Isaac Asante
Dr. Asante received his bachelorās in pharmacy from the University of Science and Technology, Ghana in 2005, after which he had his M.S. in Regulatory Sciences and Ph.D. in Clinical and Experimental Therapeutics from the University of Southern California, Los Angeles in 2014 and 2017, respectively. After his PhD, he continued his post-doctoral training in the Laboratory of Professor Stan Louie developing therapeutic interventions for oncology and ophthalmic use.
His current research focus revolves around understanding and development of novel treatment for neurodegenerative disease and cancer therapeutics. To understand these complex disease states, he has developed and validated āomicsā platform to profile healthy and diseased biological specimens. Using this platform, he has been able to use biochemical biomarker to develop and optimize therapeutic intervention development. He uses the āomicsā approach to build maps and predictive models that expands our understanding of disease pathophysiology and complements other efforts to develop therapeutic interventions that can translate quickly to the clinic.
Dr. Asante has used the omics platform to build predictive models for acute respiratory distress syndrome and colorectal cancer. Such models have been used to guide development of innovative therapeutic interventions for the traumatic brain injury and aged-related macular degeneration. He has published in high-impact journals including New England Journal of Medicine.
Dr. Asante is currently helping the fight against the COVID-19 pandemic by engineering a biodegradable nanoparticle barrier to prevent SARS-CoV2 and other microbial infections in the nasopharyngeal space.